Roche's acquired drug candidate, CT-388, demonstrated positive weight loss results in early-stage obesity trial, boosting market interest.

Roche shares rose after its drug candidate, acquired from Carmot Therapeutics, showed positive results for weight loss in an early-stage clinical trial in adults with obesity. The drug, CT-388, led to significant weight loss compared to a placebo, adding to the market interest for obesity treatments, currently dominated by Novo Nordisk and Eli Lilly, as pharma groups seek to tap into the $100bn market.

May 16, 2024
8 Articles

Further Reading